Table 1.
The main characteristics of the randomized controlled trials.
| Study | Intervention | Control | Sample size (Int/Cont) | Mean age (Int/Cont) | Parity (Int/Cont) | BMI (Int/Cont) | History of POP (Int/Cont) | Inclusion criteria | Follow-up duration |
|---|---|---|---|---|---|---|---|---|---|
| Halaska et al. (10) | Sacrospinous fixation (Transvaginal) | Mesh procedures (Transvaginal) | 168 (83/85) | 64.89 (66.41/63.37) | 2.32/2.08 | 27.62/26.81 | NA | POP-Q stage II or greater | 12 months |
| Enklaar et al. (5) | Sacrospinous hysteropexy (Transvaginal) | Manchester procedure (Transvaginal) | 434 (217/217) | 62.0 (61.0/63.0) | 3.0/3.0 | 25.4/25.2 | 83.0/77.0 | Aged 18 years or older planning to undergo a first surgery for symptomatic pelvic organ prolapse in any stage | 2 years |
| Jelovsek et al. (13) | Sacrospinous ligament fixation (SSLF; Transvaginal) | Uterosacral ligament suspension (ULS; Transvaginal and mesh) | 374 (186/188) | 57.15 (56.9/57.4) | 2.8/3.4 | 29.2/28.5 | 12.0/6.0 | POP-Q stage II-IV | 5 years |
| Barber et al. (12) | Sacrospinous ligament fixation (SSLF; Transvaginal) | Uterosacral ligament suspension (ULS; Transvaginal and mesh) | 374 (186/188) | 57.25 (57.2/57.3) | 2.0/3.0 | 29.0/28.7 | 17.0/9.0 | Aged at least 18 years undergoing vaginal surgery for stage II-IV prolapse | 2 years |
| Heinonen et al. (11) | Anterior vaginal wall mesh augmentation with concomitant sacrospinous ligament fixation (SSLF; Transvaginal and mesh) | Posterior intravaginal slingplasty (IVS; Transvaginal and mesh) | 22 (8/14) | 70.2 (68.0/73.0) | 2.0/2.0 | 24.0/27.0 | 3.0/4.032(16/16) | Patients with symptomatic vaginal vault prolapse or uterine procidentia | 3 years |